Abstract
In obese adipose tissue, chronic low-grade inflammation has been implicated in 2 metabolic dysregulation and insulin resistance (1; 2). As compared to lean subjects, in obese 3 subjects, adipose tissue promotes macrophage recruitment and a cross-talk between 4 adipocytes and macrophages, resulting in adipose tissue inflammation accompanied with high 5 levels of inflammatory cytokines such as tumor necrosis factor α (TNFα), interleukin (IL)-1β, 6 IL-6, and monocyte-chemoattractant protein 1 (MCP-1) (1-3). Pro-inflammatory cytokines 7 secreted by inflamed adipose tissue repress insulin action in metabolic organs by activating 8 stress induced kinases such as IκB kinase-β and Jun N-terminal kinase (JNK), which leads to 9 systemic insulin resistance (4-6). Moreover, increased oxidative stress in obese adipose tissue 10 contributes to adipose tissue inflammation via activation of mitogen-activated protein kinases 11 (MAPKs) including JNK and p38 (7; 8). In addition, elevated cellular levels of reactive 12 oxygen species (ROS) further stimulate pro-inflammatory gene expression via activation of 13 nuclear factor-κB (NFκB) pathways in obesity (7-10). It has been suggested that one of the 14 major sources of cellular ROS in obese adipose tissue is pro-oxidative enzymes, including 15 NADPH oxidase (9-11). Various pro-oxidative enzymes are known to be augmented in 16 adipose tissues of obese animals, whereas anti-oxidative processes related to scavenging of 17 ROS tend to be suppressed (9; 10). Accordingly, treatment with NADPH oxidase inhibitors as 18 well as anti-oxidant drugs attenuates ROS production and adipokine dysregulation, leading to 19 alleviation of metabolic disorders such as insulin resistance in obesity (9; 12). Thus, it is 20 likely that the imbalance between ROS production and scavenging in obese adipose tissue is 21 closely associated with elevated adipose tissue inflammation and metabolic dysregulation.
22
Glucose-6-phosphate dehydrogenase (G6PD), a key enzyme of the pentose 23 phosphate pathway which shunts from the glycolytic pathway, catalyzes the synthesis of 24 ribose for nucleic acid production and produces cytosolic NADPH (13). NADPH is one of respectively (10; 13). In pathological conditions such as atherosclerosis, heart failure, and 5 obesity, G6PD promotes cellular ROS production and pro-inflammatory signaling through 6 increased availability of NADPH to ROS-producing enzymes (14) (15) (16) (17) (18) (19) . On the other hands, in 7 various cell types including erythrocytes, cardiomyocytes, endothelial cells, and pancreatic β- 
20
G6PD deficiency is a common enzymopathy, affecting over 400 million people 21 worldwide (13). One of the distinctive characteristics of G6PD deficient patients is hemolytic 22 anemia which is triggered by exposure to oxidative stress. As a potential animal model of 23 human G6PD deficiency, G6PD-deficient mutant (G6PD mut ) mouse model has been 24 developed, which shows 10-15% of regular G6PD activity because of a reduction in G6PD
25
Page 4 of 49 Diabetes 5 protein expression by splicing defect (27; 28) . Since the embryo-protective role of G6PD has 1 been reported (20; 29), various effects of G6PD deficiency on metabolic processes, immune 2 responses, and organ development have been studied on G6PD mut mice (17; 18; 21; 22; 30) .
3
Furthermore, G6PD deficiency affects on albuminuria and diet-induced cardiometabolic 4 aberrations in G6PD mut mice (31; 32). However, it still remains to be elucidated the effects of 5 G6PD defect in vivo on chronic inflammation and systemic insulin resistance in diet-induced 6 obesity (DIO).
7
In this study, we have shown that G6PD mut mice exhibit improved glucose-tolerance Korea) more than 10 times to change the genetic background (Fig. S1 ). The mice were 5 genotyped by PCR as illustrated in Fig. S1 production, and its mRNA expression is up-regulated in response to oxidative stress in obese 17 adipose tissue (9). To determine whether G6PD defect may attenuate the increased ROS 18 production in DIO, the expression of NADPH oxidase subunits was examined in HFD-fed
19
WT and G6PD mut mice. As shown in Fig. 3A Adiposity and fatty liver are not alleviated in HFD-fed G6PD mut mice.
12
Aside from redox regulation, G6PD is involved in lipogenesis (14). Unexpectedly,
13
we did not detect any reduction in adiposity in G6PD mut mice compared to WT mice upon triglycerides and cholesterol were similar between WT and G6PD mut mice ( Fig. S2A and B).
20
WT and G6PD mut mice showed a similar degree of non-alcoholic fatty liver upon HFD. we examined gene expression profiles of pro-inflammatory cytokines and macrophage 8 markers. Although there were no significant differences in the expression of pro-
9
inflammatory genes between WT and G6PD mut mice upon ND ( Fig. S3 ), the mRNA level of
10
CD11c was significantly reduced in the adipose tissue of HFD-fed G6PD mut mice (Fig. 4C ).
11
In addition, both mRNA and protein levels of pro-inflammatory cytokines such as TNFα and
12
MCP-1 were decreased ( Fig. 4C and D cytokines, seemed to be slightly but not significantly increased in G6PD mut mice (Fig. 4G ).
21
These data implied that M1 polarization of adipose tissue macrophages (ATMs) appeared to 22 be partially attenuated in HFD-fed G6PD mut mice. Furthermore, the serum TNFα and MCP-1
23
were reduced while the serum adiponectin was elevated in HFD-fed G6PD mut mice compared 24 to that in HFD-fed WT mice (Fig. 4H ). Similar to the adipose tissues, mRNA levels of M1 CD11c-positive ATMs of CLS was highly expressed in the obese adipose tissue of WT BMT 10 mice, but its expression was clearly decreased in HFD-fed G6PD mut BMT mice (Fig. 7B) .
11
Upon HFD feeding, there were no significant differences in body weight, adipose tissue 12 weight, and adipocyte size between WT and G6PD mut BMT mice (Fig 7C-F ). The fasting 13 insulin level, however, was significantly lower in HFD-fed G6PD mut BMT mice compared to 14 HFD-fed WT BMT mice despite similar fasting glucose level ( Fig. 7G and H ). In addition,
15
HFD-fed G6PD mut BMT mice were more glucose tolerant than HFD-fed WT BMT mice (Fig.   16 7I). Therefore, these data indicated that reconstitution of bone marrow in WT mice with 17 G6PD mut bone marrow could alleviate insulin resistance in DIO.
19
Hematopoietic G6PD defect protects against diet-induced adipose tissue inflammation.
20
To explore whether adipose tissue inflammation might be associated with improved (Fig. 8B) . As expected, in WT mice, the transplant of G6PD mut bone marrow 2 reduced the level of G6PD mRNA in adipose tissue in DIO (Fig. 8C) . In addition, mRNA 3 levels of NADPH oxidase subunits such as NOX2 and p22phox were decreased, while that of 4 catalase was increased in the adipose tissue of HFD-fed G6PD mut BMT mice, implying that 5 the oxidative stress in the adipose tissue might be reduced by hematopoietic G6PD defect 6 (Fig. 8C) . Furthermore, mRNA levels of pro-inflammatory cytokines such as TNFα, IL-6, 7
and MCP-1 were decreased, as was the expression of M1 marker genes such as CD11c. In 8 contrast, mRNA level of adiponectin tended to be increased (Fig. 8D) (Fig. 4) . In addition, the levels of several pro-inflammatory cytokines 6 including TNFα and MCP-1 were decreased in adipose tissue and serum from HFD-fed 7 G6PD mut mice (Fig. 4) . In contrast, adiponectin having anti-inflammatory and anti-diabetic 8 effects was elevated in adipose tissue and serum from HFD-fed G6PD mut mice (Fig. 4) .
9
Moreover, G6PD mut macrophages were resistant to pro-inflammatory stimulation by LPS ( Fig.   10 5) and mediated enhanced insulin action in adipocytes and hepatocytes (Fig. 6 cells were barely detectable in the liver according to PCR genotyping (Fig. 7A ). In line with 22 this finding, the level of G6PD mRNA was not reduced in the liver of HFD-fed G6PD mut
23
BMT mice (Fig. S4) . Although further studies are definitely needed to investigate the 24 function of G6PD in Kupffer cells, our in vitro experiments (Fig. 6) propose the possibility NADPH-producing enzymes such as G6PD, ME, and IDH are abundantly expressed (14).
5
Given that NADPH production by G6PD is positively associated with lipogenic activity in 6
adipocytes (14), we have speculated that G6PD defect might affect the synthesis and/or triglycerides, and cholesterol upon ND or HFD ( Fig. 1 and S2 ). The data that serum free fatty 10 acids level were decreased in HFD-fed G6PD mut mice (Fig. 1H) the adipose tissue and liver of HFD-fed G6PD mut mice (Fig. S5) . Nevertheless, the possibility 22 that these enzymes might be relatively activated in G6PD mut mice cannot be excluded.
23
Here, we have shown that genetic G6PD defect ameliorates chronic inflammation 24 and insulin resistance in DIO. It is likely that inhibition of G6PD in obesity will reduce (Fig. S6) . Collectively, our data have suggested that manipulation of 4 G6PD activity would be one of the potential approaches for countering obesity-induced 5 metabolic disorders. and total AKT and the ratio of p-GSK3β and total GSK3β are represented as mean ± SD. *P Actin was as the loading control, GAPDH and Pan-Cadherin were used as a cytosolic marker 8 and a membrane marker, respectively. The data represent mean ± SD. *P < 0.05 and ***P < 9 0.001 vs. WT group by Student's t test. and MCP-1 in the liver. The data represent mean ± SD. *P < 0.05, **P < 0.01 and ***P < 22 0.001 vs. WT group by Student's t test. 
